Oppenheimer Reiterates Outperform Rating on Raptor Pharmaceutical on Positive Developments Supporting Their Thesis
June 26, 2013 at 10:58 AM EDT
In a report published on Wednesday, Oppenheimer analyst Boris Peaker reiterated an Outperform rating and a price target of $11 on Raptor Pharmaceutical (NASDAQ: RPTP ). In the report, Oppenheimer stated, "Raptor Pharmaceutical announced the FDA has granted orphan drug exclusivity to Procysbi. The announcement is an incremental positive, in
